{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:01:04Z","timestamp":1793642464942,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jtocrr.2024.100672","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T07:49:30Z","timestamp":1711698570000},"page":"100672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"5","author":[{"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Spils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Losmanov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1199-6520","authenticated-orcid":false,"given":"Ren-Wang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2024.100672_bib1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2024.100672_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtocrr.2024.100672_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NFL, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100672_bib4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2024.100672_bib5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s43018-022-00419-5","article-title":"Accelerating innovations in systemic therapy for pleural mesothelioma","volume":"3","author":"Fennell","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtocrr.2024.100672_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2024.100672_bib7","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib8","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2024.100672_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtocrr.2024.100672_bib10","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2022.04.014","article-title":"Revisiting \u201cBAP1ness\u201d in malignant pleural mesothelioma","volume":"17","author":"Yang","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib13","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A\u00a0subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib16","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtocrr.2024.100672_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 loss by immunohistochemistry predicts improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.jtocrr.2024.100672_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtocrr.2024.100672_bib20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"de Reyni\u00e8s","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100672_bib21","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.3390\/cancers14204997","article-title":"Dissecting the immunological profiles in NSD3-amplified LUSC through integrative multi-scale analyses","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2024.100672_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtocrr.2024.100672_bib23","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.7150\/thno.53649","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.jtocrr.2024.100672_bib24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jtocrr.2024.100672_bib25","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtocrr.2024.100672_bib26","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtocrr.2024.100672_bib27","first-page":"89","article-title":"Practical methods for tissue microarray construction","volume":"103","author":"Fedor","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.jtocrr.2024.100672_bib28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41420-023-01307-2","article-title":"MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma","volume":"9","author":"Yang","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jtocrr.2024.100672_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtocrr.2024.100672_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2024.100672_bib31","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtocrr.2024.100672_bib32","doi-asserted-by":"crossref","first-page":"a022657","DOI":"10.1101\/cshperspect.a022657","article-title":"Mismatch repair during homologous and homeologous recombination","volume":"7","author":"Spies","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtocrr.2024.100672_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib36","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","article-title":"Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma","volume":"11","author":"Ladanyi","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.jtocrr.2024.100672_bib37","article-title":"Matter\u00a0of\u00a0TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy","volume":"9","author":"Harber","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2024.100672_bib38","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","article-title":"Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated T cell suppression","volume":"11","author":"Lievense","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib39","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s43018-021-00276-8","article-title":"LAG-3 and PD-1 blockade raises the bar for melanoma","volume":"2","author":"Robert","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtocrr.2024.100672_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jtocrr.2024.100672_bib42","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","article-title":"Antigen dominance hierarchies shape TCF1(+) progenitor CD8 T cell phenotypes in tumors","volume":"184","author":"Burger","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtocrr.2024.100672_bib43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtocrr.2024.100672_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib45","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers13020282","article-title":"The search for an interesting partner to combine with PD-L1 blockade in mesothelioma: focus on TIM-3 and LAG-3","volume":"13","author":"Marcq","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2024.100672_bib46","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1038\/s41388-018-0153-z","article-title":"How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations","volume":"37","author":"Rehrauer","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.jtocrr.2024.100672_bib47","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.3390\/cancers14153678","article-title":"BAP1 loss promotes suppressive tumor immune microenvironment via upregulation of PROS1 in Class 2 uveal melanomas","volume":"14","author":"Kaler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2024.100672_bib48","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells","volume":"3","author":"Li","year":"2022","journal-title":"Cell Reprod Med"},{"key":"10.1016\/j.jtocrr.2024.100672_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.603223","article-title":"BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune check-point inhibitors and poly(ADP-ribose) polymerase inhibitors","volume":"11","author":"Dudnik","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2024.100672_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","article-title":"MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects","volume":"22","author":"Verma","year":"2021","journal-title":"Nat Immunol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324000420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364324000420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T05:17:25Z","timestamp":1716527845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364324000420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666364324000420"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100672","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100672"}}